A new meta-analysis of prospective studies finds artificial intelligence performs similarly to dermatologists in melanoma detection, although more rigorous research is needed before it can be considered as a reliable decision-support tool in routine care.
The California insurer is continuing the program, called Virtual Blue, but also looking to add more virtual care into its standard offerings.
Yuvezzi treats presbyopia, or blurry vision due to aging, and is available at retail pharmacies or PHIL, an ePharmacy platform.
One year after FDA approval, Journavx (suzetrigine) offers a promising non-opioid option for acute pain, but experts have concerns about long-term safety, opioid-sparing effects and real-world use.
Lenox Hill Hospital’s controversial $2 billion redevelopment includes a new mental health clinic, a shorter tower, and expanded emergency, surgical, and maternity facilities.
Dermatology performance measures need to be streamlined and redesigned to better capture meaningful patient outcomes while reducing administrative burden and aligning with value-based care.
The two oral GLP-1s will battle for market share. Foundayo is a small-molecule drug that can be taken with food. Some data suggest that oral Wegovy is slightly better at producing weight loss.
Women who experience menopause before age 40 face a significantly higher risk of coronary heart disease, according to new research by researchers at Northwestern Medicine.
USF Health researchers have discovered how opioid receptors work in reverse, which could allow for medications to boost pain relief without causing dangerous side effects.
The Phoenix-based nonprofit health system had $16 billion in revenues in 2025 and reported $1.1 billion in community benefits in its 2025 annual report.
Doctors Without Borders has accused Gilead of restricting access to its HIV prevention drug lenacapavir by refusing humanitarian sales and limiting supply, arguing this is hindering global efforts to expand HIV prevention in high-need regions.
A new report found that despite widespread AI adoption in U.S. health systems, many patients still struggle to access care due to gaps in communication, trust and care navigation.
Alkermes has initiated a phase 3 clinical program evaluating alixorexton for narcolepsy type 1 and type 2, with additional development underway for idiopathic hypersomnia.
A long-term extension trial of 389 patients found Attruby significantly cut death risk in transthyretin amyloid cardiomyopathy, with no new safety concerns identified.
Eli Lilly announced this morning that the FDA has approved its oral GLP-1, orforglipron, which the company is marketing under the brand name Foundayo. The competition between Foundayo and oral Wegovy is expected to be fierce.
A new preclinical study found that inhibiting the enzyme LSD1 can activate the skin’s immune system and suppress tumor growth, pointing to a potential new topical treatment for skin cancer.
A study published March 20 in Nature found that a mechanosensitive piezo1–IL-33 signaling pathway in vascular endothelial cells is associated with pulmonary fibrosis and may represent a potential therapeutic target.
Researchers found that lung function showed only a weak relationship with quality-of-life outcomes, highlighting perhaps the value of broader patient-reported or caregiver-reported outcomes in clinical care and research.
Van Beek, a dermatologic surgeon at University of Iowa Health Care and a clinical professor at the university’s Carver College of Medicine, spoke to MHE about what she sees as the major shortcomings of MIPS and AAD's DataDerm.
Novo Nordisk is offering the subscriptions through telehealth providers Ro, WeightWatchers and LifeMD. Others are expected to follow.
Get clear, expert-backed answers to the biggest questions surrounding the Great Healthcare Plan, with insights from Emma Wager of KFF and industry experts including Jeffrey Casberg, Lindsay Bealor Greenleaf and Luke Greenwalt. This FAQ breaks down what proposed changes to drug pricing, PBMs, subsidies and insurance coverage could mean for your organization — and what to watch as policies take shape.
Preliminary data from a preclinical study show that vialinin-A, a compound isolated from Chinese mushrooms, is an antioxidant that has an anti-inflammatory effect.
Incyte’s phase 3 STOP-HS data show that povorcitinib improved symptoms of moderate to severe hidradenitis suppurativa in most patients over 54 weeks with a generally well-tolerated safety profile.
Doctors should consider both cultural habits and genetic differences when diagnosing skin conditions in Asian children, according to Joseph Lam, M.D., as some are linked to traditions, others to inherited risks and some remain not fully understood.
Adults with moderate atopic dermatitis reported rapid itch relief, better sleep, and improved daily functioning after eight weeks using Opzelura topical cream.
Sunlight can be both harmful and beneficial, meaning it’s important for dermatologists to give personalized advice to each patient, according to this morning’s 2026 American Academy of Dermatology session
A new patient survey reveals gaps in treatment persistence and awareness among patients with vitiligo.
Lack of measures that take into account severity hinders participation by dermatologists, says the University of Iowa Health Care dermatologic surgeon.
Arthropods can cause or mimic a wide range of skin diseases, making accurate recognition, diagnosis and management essential in dermatologic care.
